Research progress in targeting GPRC5D for the treatment of multiple myeloma
10.3760/cma.j.cn121090-20240322-00109
- VernacularTitle:靶向GPRC5D治疗多发性骨髓瘤的研究进展
- Author:
Jiaying AN
1
;
Mengmeng PAN
;
Wanyan OUYANG
;
Jianqing MI
Author Information
1. 上海交通大学医学院附属瑞金医院血液科，上海血液学研究所，组学与疾病全国重点实验室，国家转化医学研究中心，上海 200025
- From:
Chinese Journal of Hematology
2024;45(9):883-888
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma (MM) is a malignant disease caused by the abnormal clonal proliferation of plasma cells, accounting for 10% of all hematologic cancers. In recent years, with the development and application of targeted drugs, a significant progress has been observed in the treatment methods of MM, but patients still face the challenges of relapse and drug resistance. Moreover, G protein-coupled receptor class C Group 5 member D (GPRC5D) is highly expressed in MM cells independently of B cell maturation antigen (BCMA) and is a highly promising target following BCMA. Aside from emphasizing the therapeutic efficacy and safety of targeting GPRC5D for the treatment of MM, this study also provides a prospective view on the mechanisms of drug resistance and relapse associated with GPRC5D-targeted therapies, as well as the timing of sequential or combined treatment strategies involving the dual targeting of both GPRC5D and BCMA.
